

**Urgent Field Safety Notice**

(Singapore version)

**Eckert & Ziegler  
BEBIG GmbH**Robert-Rössle-Str. 10  
13125 Berlin  
Germany  
[www.bebig.com](http://www.bebig.com)Contact: Bernd Schumacher  
Tel: +49(0)30941084-130  
E-Mail: [orders.germany2@bebig.com](mailto:orders.germany2@bebig.com)

Subject: Offset of Depth Dose Curve

Commercial Name of Affected Product: Ru-106 Eye Applicator

Types: Ru6.A03, Ru6.A04, Ru6.A05, Ru6.A06,  
Ru6.A07, Ru6.A09, Ru6.A13, Ru6.A14

Reference: UFSN-2019Ru-106

Date of Notification: 15 Aug. 2019

Type of Action: Information / Recall

**Description of Problem:**

- This notice refers to the Ru-106 Eye Applicators sent by Eckert & Ziegler BEBIG from 1 April 2019 to 7 August 2019.
- Because of a systematic offset in axial positioning, the data of the Depth Dose Curve referring to z-coordinate = 1, 2, 3 ... 10 mm have been measured with a shift of +0.35 mm.  
This results in a deviation of the certified dose rate against the correct value. For most applicator models the relevant range for the treatment planning is  $z = 0-6$  mm. For these models the actual depth dose rates of the applicators are 7-18% higher than certified.  
For the small models CCX and CIA the relevant range for the treatment planning is  $z = 0-4$  mm. For these models the actual depth dose rates of the applicators are 9-18% higher than certified.
- The deviation can lead to an overdosage of 7–18% at the prescription point and to organs at risk, depending on the clinical practice.
- The user is advised to use the corrected data provided for each individual applicator as an attachment to this notice.

**Note:** For several decades the certified total uncertainty of the Ru-106 Eye Applicators dose rate was 20%. Since April 2019 it was reduced to 11% by various improvements. Due to the quadratic calculation of uncertainties and for a confidence level of 95%, the current failure leads to a maximum total deviation of 21%. This is close to the former uncertainty which had been the basis for the current clinical practice.

Managing Directors:  
Dr. Harald Hasselmann  
Dirk WarmuthBerlin Office:  
Amtsgericht Charlottenburg  
Reg.-Nr. HRB 42949 B  
USt.-ID-Nr.: DE 137169788Bank Account:  
Commerzbank AG  
Kto.: 0424648  
BLZ: 12040000


This notice needs to be passed on to all those who need to be aware within your organisation or to any organisation, including the Chairman Medical Board and/or relevant Head-of-Departments, where the devices have been transferred to.

Please reply to this email confirming that you have received and understood this information and that you have forwarded it to the people which already have received the named products or will receive them.

The undersign representative from Eckert & Ziegler BEBIG GmbH confirms that this notice has been notified to the appropriate Regulatory Agency.

We sincerely apologise for any inconvenience and thank you in advance for your cooperation. For further information please feel free to contact us.

Kind regards,



Bernd Schumacher  
Head of Quality Management

P06D002e Rev.6

## **CONFIRMATION**

**Urgent Field Safety Notice from Eckert & Ziegler BEBIG GmbH,  
Reference UFSN-2019Ru106**

---

**This is to confirm that we have received and understood the Field Safety Notice. It was forwarded inside our clinic to the respective personnel.**

**Name of clinic:** .....

**Country, City:** .....

**Name:** .....

**Signature, date:** .....

## Urgent Field Safety Notice Attachment

**This notice must be passed on to all those who need to be aware within your organisation or to any organisation where the devices have been transferred to.**

**Eckert & Ziegler  
BEBIG GmbH**

Robert-Rössle-Str. 10  
13125 Berlin  
Germany  
www.bebig.com

Subject: Offset of Depth Dose Curve


Reference: **UFSN-2019Ru106**

Date of notification: 15 Aug 2019

With this attachment, we provide to you the corrected dose rate curve  $\dot{D}(z)$  along the central axis of each individual Ru-106 Eye Applicator concerned by the offset. The correction has been performed by interpolation to the dose rate at the respective distances to the surface  $z_{\text{new}}$ .

The graph replaces that one given on the appendix of the certificate. In the table, the measured dose rates  $\dot{D}_{\text{meas}}$  at the corrected distances ( $z_{\text{corr}} = 1.35, 2.35, \dots, 10.35$  mm) are stated together with the interpolated data  $\dot{D}_{\text{int}}$  ( $z_{\text{new}} = 1.00, 2.00, \dots, 10.00$  mm).

Serial number of applicator CCB 2739  
Certificate no. 53819  
Reference date 13.06.2019



\* Due to technical reasons the value at 0.83 mm was measured correctly and therefore does not change.

\*\* Extrapolated data according the previous and new fit function.

\*\*\* Relative deviation between previous and corrected dose rates

Please note: Since we have not carried out a new measurement, we are unfortunately unable to issue a new certificate for you. Hence please use this information as a substitute for the corresponding appendix of the certificate.

Managing Directors:  
Dr. Harald Hasselmann  
Dirk Warmuth

Berlin Office:  
Amtsgericht Charlottenburg  
Reg.-Nr. HRB 42949 B  
USt.-ID-Nr.: DE 137169788

Bank Account:  
Commerzbank AG  
Kto.: 0424648  
BLZ: 12040000